Grinnan Daniel, Farr Grant, Fox Adam, Sweeney Lori
Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.
Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.
J Diabetes Res. 2016;2016:2481659. doi: 10.1155/2016/2481659. Epub 2016 Jun 8.
Pulmonary hypertension is a progressive disorder which often leads to right ventricular failure and death. While the existing classification system for pulmonary hypertension does not account for the impact of diabetes mellitus, evidence is emerging that suggests that diabetes is associated with pulmonary hypertension and that diabetes modifies the course of pulmonary hypertension. There is also growing radiographic, hemodynamic, biochemical, and pathologic data supporting an association between diabetes and pulmonary hypertension. More robust epidemiologic studies are needed to confirm an association between diabetes and pulmonary hypertension and to show that diabetes is a disease modifier in pulmonary hypertension. In addition, evaluating the effects of glucose control in animals with pulmonary hypertension and diabetes (as well as in humans) is warranted.
肺动脉高压是一种进行性疾病，常导致右心室衰竭和死亡。虽然现有的肺动脉高压分类系统未考虑糖尿病的影响，但越来越多的证据表明，糖尿病与肺动脉高压相关，且糖尿病会改变肺动脉高压的病程。此外，越来越多的影像学、血流动力学、生化及病理学数据也支持糖尿病与肺动脉高压之间存在关联。需要开展更有力的流行病学研究来证实糖尿病与肺动脉高压之间的关联，并证明糖尿病是肺动脉高压的病情影响因素。此外，评估血糖控制对肺动脉高压合并糖尿病动物（以及人类）的影响是有必要的。
